• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Infection risk and adoption trends in hemodialysis catheters: New real-world evidence

Infection risk and adoption trends in hemodialysis catheters: New real-world evidence

by Truveta staff | Jul 31, 2025 | Research

Can catheter design impact patient safety? That’s the question of a new peer-reviewed study from Medical Components, Inc. (Medcomp), based on a retrospective analysis of 3,546 catheter insertions captured in Truveta Data. Used to deliver life-sustaining dialysis...
GLP-1 RA prescription trends: January 2018 – June 2025

GLP-1 RA prescription trends: January 2018 – June 2025

by Truveta Research | Jul 24, 2025 | Research

Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
Pediatric fluoride prescriptions fall across the US

Pediatric fluoride prescriptions fall across the US

by Truveta Research | Jul 23, 2025 | Research, Research Insights

The rate of pediatric fluoride prescriptions per all prescriptions decreased by 54.3% from the first quarter of 2022 (5.0 per 1,000 prescriptions) to the second quarter of 2025 (2.3 per 1,000 prescriptions). Across the study period, the 10 US states with lowest...
Truveta experts: Real-world trends in Rituxan biosimilar adoption

Truveta experts: Real-world trends in Rituxan biosimilar adoption

by Truveta staff | Jul 21, 2025 | Research

In this Truveta experts spotlight, Jared Kern and Vidya Venkataraman, PhD explored trends in the use of Rituxan biosimilars between 2018 and 2024. Their analysis of Truveta Data reveals how patient access and switching behavior has evolved over time. Jared Kern is a...
Shifting trends in initiation of disease-modifying therapies for multiple sclerosis

Shifting trends in initiation of disease-modifying therapies for multiple sclerosis

by Truveta Research | Jul 16, 2025 | Research, Research Insights

The proportion of patients initiating treatment for multiple sclerosis (MS) with a high efficacy disease-modifying therapy (DMT) more than doubled from 2018 to 2025, reflecting evolving clinical guidelines. Use of oral and injectable therapies showed a gradual decline...
New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do

New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do

by Truveta Research | Jul 14, 2025 | Research, Research Insights

In 2023, the American Academy of Pediatrics (AAP) released groundbreaking new guidelines recommending early treatment for childhood and adolescent obesity—including the use of medications for weight management in adolescents and cautioning against the common practice...
Truveta experts: Treatment trends for trigeminal neuralgia

Truveta experts: Treatment trends for trigeminal neuralgia

by Truveta staff | Jul 9, 2025 | Research

This post kicks off our new series, Truveta experts— a spotlight on the data scientists, researchers, clinicians, and analysts working behind the scenes to drive healthcare research forward with real-world data. Our first contributor is Mantas Dmukauskas, PhD, a...
Real-world survival outcomes for CRT and CCM therapies align with landmark trials

Real-world survival outcomes for CRT and CCM therapies align with landmark trials

by Truveta staff | Jun 30, 2025 | Research

A new peer-reviewed study from researchers at Saint Luke’s Mid America Heart Institute, Impulse Dynamics, and the Cardiovascular Research Foundation demonstrates the power of real-world data to evaluate device therapies. By evaluating survival outcomes of cardiac...
Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines

Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines

by Truveta Research | Jun 26, 2025 | Research, Research Insights

Thimerosal is a preservative contained in some vaccines, which has been used and considered safe for decades. During the June 2025 ACIP meeting, a presentation and vote on the use of thimerosal is scheduled to take place. During the 2024-2025 respiratory virus season,...
Biosimilar use is on the rise – but 1 in 8 patients return to Humira

Biosimilar use is on the rise – but 1 in 8 patients return to Humira

by Truveta Research | Jun 23, 2025 | Research, Research Insights

Switching from bio-originator Humira to a biosimilar peaked in April 2024 – the month an important formulary change took effect – and remains higher than 2023, suggesting growing adoption of biosimilars. More than 1 in 8 patients who initiated a biosimilar...
« Older Entries
Next Entries »

Share this


Recent posts

  • Truveta experts: Biomarker testing trends in metastatic non-small cell lung cancer (NSCLC)
  • Multiple sclerosis: Real-world treatment patterns and outcomes
  • ISPE 2025: Real-world data survival patterns in glioblastoma patients

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.